Hypermutation alludes to an excessive number of specific guanine-to-adenine (G- >A) substitutions in proviral DNA and this phenomenon is attributed to the catalytic activity of cellular APOBECs. Population studies relating hypermutation and the progression of infection by human immunodeficiency virus type 1 (HIV-1) have been performed to elucidate the effect of hypermutation on the natural course of HIV-1 infection. However, the many different approaches employed to assess hypermutation in nucleotide sequences render the comparison of results difficult. This study selected 157 treatment-naive patients and sought to correlate the hypermutation level of the proviral sequences in clinical samples with demographic variables, HIV-1 RNA viral load, and the level of CD4+ T cells. Nested touchdown polymerase chain reaction (PCR) was performed with specific primers to detect hypermutation in the region of HIV-1 integrase, and the amplified sequences were run in agarose gels with HA-Yellow. The analysis of gel migration patterns using the k-means clustering method was validated by its agreement with the results obtained with the software Hypermut. Hypermutation was found in 31.2% of the investigated samples, and a correlation was observed between higher hypermutation levels and higher viral load levels. These findings suggest a high frequency of hypermutation detection in a Brazilian cohort, which can reflect a particular characteristic of this population, but also can result from the method approach by aiming at hypermutation-sensitive sites. Furthermore, we found that hypermutation events are pervasive during HIV-1 infection as a consequence of high viral replication, reflecting its role during disease progression.
Get full access to this article
View all access options for this article.
References
1.
RathoreA, ChatterjeeA, YamamotoN, and DholeTN: Absence of H186R polymorphism in exon 4 of the APOBEC3G gene among North Indian individuals. Genet Test, 2008; 12:453–456.
2.
ManskyLM and TeminHM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol, 1995; 69:5087–5094.
3.
EigenM: Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA, 2002; 99:13374–13376.
4.
PerelsonAS, NeumannAU, MarkowitzM, LeonardJM, and HoDD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science, 1996; 271:1582–1586.
5.
LiY, HuiH, BurgessCJ, et al.: Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: Evidence for limited defectiveness and complementation. J Virol, 1992; 66:6587–6600.
6.
JohnstonR: HIV cure: Controversy, consensus, and a consortium. AIDS Res Hum Retroviruses, 2010; 26:943–946.
7.
SheehyAM, GaddisNC, ChoiJD, and MalimMH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002; 418:646–650.
8.
MangeatB, TurelliP, CaronG, FriedliM, PerrinL, and TronoD: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature, 2003; 424:99–103.
9.
GabuzdaDH, LawrenceK, LanghoffE, et al.: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol, 1992; 66:6489–6495.
10.
GaddisNC, ChertovaE, SheehyAM, HendersonLE, and MalimMH: Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol, 2003; 77:5810–5820.
11.
RibeiroAC, Maia e SilvaA, Santa-MartaM, et al.: Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol, 2005; 79:823–833.
12.
OpiS, KaoS, Goila-GaurR, et al.: Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol, 2007; 81:8236–8246.
13.
JuliasJG and PathakVK: Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J Virol, 1998; 72:7941–7949.
14.
JaniniM, RogersM, BirxDR, and McCutchanFE: Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol, 2001; 75:7973–7986.
15.
MbisaJL, BarrR, ThomasJA, et al.: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol, 2007; 81:7099–7110.
16.
ArmitageAE, DeforcheK, ChangCH, et al.: APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete “all or nothing” phenomenon. PLoS Genet, 2012; 8:e1002550.
17.
RussellRA, MooreMD, HuWS, and PathakVK: APOBEC3G induces a hypermutation gradient: Purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology, 2009; 6:16.
18.
FouratiS, Lambert-NiclotS, SoulieC, et al.: HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother, 2012; 67:2323–2326.
19.
FouratiS, MaletI, LambertS, et al.: E138K and M184I mutations in HIV-1 reverse transcriptase co-emerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS, 2012; 26:1619–1624.
20.
PaceC, KellerJ, NolanD, et al.: Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol, 2006; 80:9259–9269.
21.
LandAM, BallTB, LuoM, et al.: Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol, 2008; 82:8172–8182.
22.
AnP, BleiberG, DuggalP, et al.: APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol, 2004; 78:11070–11076.
23.
UlengaNK, SarrAD, HamelD, SankaleJL, MboupS, and KankiPJ: The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses, 2008; 24:1285–1290.
24.
KourtevaY, De PasqualeM, AllosT, McMunnC, and D'AquilaRT: APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology, 2012; 430:1–9.
25.
PiantadosiA, HumesD, ChohanB, McClellandRS, and OverbaughJ: Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol, 2009; 83:7805–7814.
26.
ChoSJ, DrechslerH, BurkeRC, ArensMQ, PowderlyW, and DavidsonNO: APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol, 2006; 80:2069–2072.
27.
ReddyK, WinklerCA, WernerL, et al.: APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS, 2010; 24:195–204.
28.
SanabaniS, Kleine NetoW, KalmarEM, DiazRS, JaniniLM, and SabinoEC: Analysis of the near full length genomes of HIV-1 subtypes B, F and BF recombinant from a cohort of 14 patients in Sao Paulo, Brazil. Infect Genet Evol, 2006; 6:368–377.
29.
KijakGH, JaniniLM, TovanabutraS, et al.: Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology, 2008; 376:101–111.
30.
KijakGH, JaniniM, TovanabutraS, et al.: HyperPack: A software package for the study of levels, contexts, and patterns of APOBEC-mediated hypermutation in HIV. AIDS Res Hum Retroviruses, 2007; 23:554–557.
31.
MullerW, HattesohlI, SchuetzHJ, and MeyerG: Polyethylene glycol derivatives of base and sequence specific DNA ligands: DNA interaction and application for base specific separation of DNA fragments by gel electrophoresis. Nucleic Acids Res, 1981; 9:95–119.
32.
ThompsonJD, GibsonTJ, and HigginsDG: Multiple sequence alignment using ClustalW and ClustalX. Curr Protocall Bioinform, 2002; Chapter 2:Unit 2 3.
33.
RosePP and KorberBT: Detecting hypermutations in viral sequences with an emphasis on G –>A hypermutation. Bioinformatics, 2000; 16:400–401.
34.
MacQueenJ: Some methods for classification and analysis of multivariate observations. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, 1967; 1:281–297.
35.
SchneiderCA, RasbandWS, and EliceiriKW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 2012; 9:671–675.
36.
SharkeyME, TeoI, GreenoughT, et al.: Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med, 2000; 6:76–81.
37.
KomninakisSV, SantosDE, SantosC, OliverosMP, SanabaniS, and DiazRS: HIV-1 proviral DNA loads (as determined by quantitative PCR) in patients subjected to structured treatment interruption after antiretroviral therapy failure. J Clin Microbiol, 2012; 50:2132–2133.
38.
EggerS, PetoumenosK, KamarulzamanA, et al.: Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr, 2009; 50:513–520.
39.
SuspeneR, RusniokC, VartanianJP, and Wain-HobsonS: Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucl Acids Res, 2006; 34:4677–4684.
40.
GoodenowM, HuetT, SaurinW, KwokS, SninskyJ, and Wain-HobsonS: HIV-1 isolates are rapidly evolving quasispecies: Evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr, 1989; 2:344–352.
41.
WeiM, XingH, HongK, et al.: Biased G-to-A hypermutation in HIV-1 proviral DNA from a long-term non-progressor. AIDS, 2004; 18:1863–1865.
42.
KiefferTL, KwonP, NettlesRE, HanY, RaySC, and SilicianoRF: G– >A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol, 2005; 79:1975–1980.
43.
VartanianJP, MeyerhansA, SalaM, and Wain-HobsonS: G– >A hypermutation of the human immunodeficiency virus type 1 genome: Evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci USA, 1994; 91:3092–3096.
44.
MartinezMA, VartanianJP, and Wain-HobsonS: Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci USA, 1994; 91:11787–11791.
45.
Wain-HobsonS, SonigoP, GuyaderM, GazitA, and HenryM: Erratic G– >A hypermutation within a complete caprine arthritis-encephalitis virus (CAEV) provirus. Virology, 1995; 209:297–303.
46.
DinosoJB, KimSY, SilicianoRF, and BlanksonJN: A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis, 2008; 47:102–104.
47.
GandhiSK, SilicianoJD, BaileyJR, SilicianoRF, and BlanksonJN: Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol, 2008; 82:3125–3130.
48.
SousaMM, KrokanHE, and SlupphaugG: DNA-uracil and human pathology. Mol Aspects Med, 2007; 28:276–306.
49.
XuH, ChertovaE, ChenJ, et al.: Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology, 2007; 360:247–256.
50.
SkinnerLM, LamersSL, SandersJC, EysterME, GoodenowMM, and KatzmanM: Analysis of a large collection of natural HIV-1 integrase sequences, including those from long-term nonprogressors. J Acquir Immune Defic Syndr Hum Retrovirol, 1998; 19:99–110.
51.
PimentaJR, ZuccheratoLW, DebesAA, et al.: Color and genomic ancestry in Brazilians: A study with forensic microsatellites. Hum Hered, 2006; 62:190–195.
52.
BizinotoMC, LealE, DiazRS, and JaniniLM: Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians. AIDS Res Hum Retroviruses, 2011; 27:137–141.
53.
SchuurmanR, DemeterL, ReichelderferP, TijnagelJ, de GrootT, and BoucherC: Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol, 1999; 37:2291–2296.
54.
ChangJ, NaifHM, LiS, SullivanJS, RandleCM, and CunninghamAL: Twin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitro. J Virol, 1996; 70:7792–7803.
55.
NaifHM, LiS, AlaliM, et al.: Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol, 1999; 73:4866–4881.
56.
AnP, DuggalP, WangLH, et al.: Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet, 2007; 3:e19.
57.
SimãoLNAW, ZukurovJPL, BuenoJ, BizinotoMCS, NunesERM, RodriguesF, SoaneMM, LimaML, DiazRS, and JaniniLM: APOBEC3G-related motifs and subtype analysis of human immunodeficiency virus type 1 Vif sequences in Sao Paulo, Brazil. Brasília: Virus Rev Res, 2009; 14.
58.
SimonV, ZennouV, MurrayD, HuangY, HoDD, and BieniaszPD: Natural variation in Vif: Differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog, 2005; 1:e6.
59.
ChaudharyM, KashyapB, GautamH, SainiS, and BhallaP: Use of surrogate markers to predict the HIV disease stage and time to initiate antiretroviral therapy in developing countries. J Int Assoc Physicians AIDS Care (Chic), 2008; 7:259–264.
60.
MellorsJW, RinaldoCRJr, GuptaP, WhiteRM, ToddJA, and KingsleyLA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 1996; 272:1167–1170.
61.
SmithRJ, OkanoJT, KahnJS, BodinEN, and BlowerS: Evolutionary dynamics of complex networks of HIV drug-resistant strains: The case of San Francisco. Science, 2010; 327:697–701.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
